ImmuPharma Files New Patent Application for P140:

AI SummaryClose X

ImmuPharma PLC has filed a new patent application for P140, a first-in-class "Immunormalizer," with the potential for 20 years of commercial exclusivity. The application covers a novel diagnostic test to identify a subpopulation of patients with Type M immune disorder who are P140 super-responders, applicable to up to 50 autoimmune diseases. This precision treatment approach aims to improve patient selection for clinical trials, potentially leading to smaller, faster, and more successful trials. The autoimmune diagnostics market is valued at over $10 billion globally, while the therapeutic market is over $100 billion annually.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings